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aspase-3 is a cysteine protease located in both the
cytoplasm and mitochondrial intermembrane space
that is a central effector of many apoptotic path-
ways. In resting cells, a subset of caspase-3 zymogens is
S-nitrosylated at the active site cysteine, inhibiting enzyme
activity. During Fas-induced apoptosis, caspases are deni-
trosylated, allowing the catalytic site to function. In the
current studies, we sought to identify the subpopulation of
C
 
caspases that is regulated by S-nitrosylation. We report
that the majority of mitochondrial, but not cytoplasmic,
caspase-3 zymogens contain this inhibitory modiﬁca-
 
tion. In addition, the majority of mitochondrial caspase-9
 
is S-nitrosylated. These studies suggest that S-nitrosylation
plays an important role in regulating mitochondrial cas-
pase function and that the S-nitrosylation state of a given
protein depends on its subcellular localization.
 
Introduction
 
Apoptosis is a tightly regulated cell death program that
 
removes excess or unwanted cells from organisms. Dysregu-
lated apoptosis may be involved in the pathogenesis of dis-
eases such as cancer, neurodegeneration, and autoimmunity
(Thompson, 1995). The apoptotic program is executed by
the caspase family of cysteine proteases that are expressed as
inactive zymogens in cells and cleaved to form active tet-
rameric enzymes. Initiator caspases (e.g., caspases-8, -9, and
-10) activate downstream effector caspases (e.g., caspases-3,
-6, and -7), which in turn cleave specific cellular targets, re-
sulting in cell death (Thornberry and Lazebnik, 1998).
Mitochondria serve as a central integrator of many apop-
totic pathways. Several proapoptotic molecules are stored in
the mitochondrial intermembrane space including apoptosis
 
inhibitory factor (Susin et al., 1996, 1999b), cytochrome 
 
c
 
 (Li
et al., 1997b), and a subset of caspase-2, -3, and -9 zymogens
(Mancini et al., 1998; Krajewski et al., 1999; Susin et al.,
1999a). When mitochondria receive an apoptotic signal, these
proteins are released into the cytoplasm, triggering the cell sui-
cide program. The percentage of caspase zymogens found in
mitochondria is variable. In rat heart and brain, 90% of cas-
pase-9 zymogens are mitochondrial (Krajewski et al., 1999),
whereas only 10% of caspase-3 zymogens are found in mito-
chondria in HeLa cells (Mancini et al., 1998). Since caspases
are activated in a cascade fashion, activation and release of a
small pool of mitochondrial caspases may activate a much
larger pool of cytoplasmic caspases. In addition, sequestering
caspases in mitochondria may prevent inappropriate apoptosis
by removing the proteases from cytoplasmic targets.
Apoptosis is also regulated by intracellular nitric oxide
(NO)* production. NO can be either pro- or antiapoptotic.
The proapoptotic effects of NO may be mediated by DNA
damage, leading to p53 activation (Messmer and Brune,
1996), proteasome inhibition (Glockzin et al., 1999), and/
or cytochrome 
 
c
 
 release from mitochondria, resulting from
activation of the mitochondrial permeability transition pore
(Messmer et al., 1996; Balakirev et al., 1997; Hortelano et
al., 1997) or damage of mitochondrial membrane phospho-
lipids (Ushmorov et al., 1999). NO is thought to exert its
antiapoptotic effects through upregulation of protective pro-
teins such as heat shock protein 70 (Kim et al., 1997a),
heme oxygenase (Kim et al., 1995), and Bcl-2 (Genaro et al.,
1995; Suschek et al., 1999): an increase in cGMP levels
(Kim et al., 1997a,b), a decrease in ceramide levels (De Na-
dai et al., 2000), and/or S-nitrosylation of a critical cysteine
residue expressed in the catalytic site of all caspase members
(Dimmeler et al., 1997; Kim et al., 1997b, 2000; Li et al.,
1997a; Mannick et al., 1999; Rossig et al., 1999).
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We reported previously that a subset of caspase-3 zymogens
is inhibited by S-nitrosylation of the catalytic site cysteine in
unstimulated human lymphocyte cell lines. Upon activation
of the Fas apoptotic pathway, the zymogens are denitrosy-
lated, allowing the enzyme to function (Mannick et al., 1999).
The studies did not identify the subpopulation of caspase-3
that is regulated by S-nitrosylation and did not analyze endog-
enous S-nitrosylation of other caspase zymogens. In the cur-
rent studies, we determined whether mitochondrial caspase-3
is the subpopulation regulated by S-nitrosylation and whether
caspase-9 zymogens also are endogenously S-nitrosylated.
 
Results and discussion
 
The majority of mitochondrial but not cytoplasmic 
caspase-3 is S-nitrosylated
 
Mitochondrial and cytoplasmic cellular fractions were iso-
lated from a human B cell line (10C9) using differential cen-
trifugation. The purity of the subcellular fractions was
confirmed by superoxide dismutase (SOD1) (cytoplasm), cy-
tochrome 
 
c
 
 (mitochondrial intermembrane space), and cyto-
chrome oxidase (mitochondrial matrix) immunoblot analysis
(Fig. 1). Caspase-3 or control proteins were immunoprecipi-
tated from the mitochondrial and cytoplasmic fractions using
a caspase-3–specific monoclonal antibody or equal concentra-
tions of an isotype-matched control antibody. Caspase-3 was
immunoprecipitated efficiently with its specific antibody but
not with control antibody (Fig. 2 A). Silver stains indicated
that associated proteins did not significantly contaminate the
caspase-3 immunoprecipitates (Fig. 2 A).
S-nitrosothiol (SNO) bonds in immunoprecipitated pro-
teins were measured by reduction/chemiluminescence as de-
scribed (Fang et al., 1998). Immunoprecipitated caspase-3
zymogen was significantly more S-nitrosylated in mitochon-
dria than in cytoplasm (Fig. 2, B and D, and Fig. 4). Similar
results were obtained using two additional human cell lines
(CEM and U937). If caspases are S-nitrosylated on a single
cysteine residue, as has been suggested by studies in vitro
(Dimmeler et al., 1997; Kim et al., 1997b; Rossig et al.,
Figure 1. Isolation of mitochondrial and cytoplasmic cellular 
fractions. 10C9 cells were fractionated into mitochondrial (M) and 
cytoplasmic (C) fractions by differential centrifugation. Equal 
amounts of each fraction were electrophoresed, and the relative 
levels of cytochrome c (left), cytochrome oxidase subunit IV (COX; 
middle), and SOD1 (right) in each fraction were determined by 
immunoblotting. Molecular weights are indicated on the left. The 
results are representative of one of three separate experiments.
Figure 2. S-Nitrosylation of mitochondrial and cytoplasmic 
caspase-3. (A) Caspase-3 immunoprecipitation. Proteins were 
immunoprecipitated from mitochondrial (M) and cytoplasmic (C) 
cellular fractions using a caspase-3–specific monoclonal anti-
body (C3) or equal concentrations of an isotype-matched control 
antibody (Ig). Immunoprecipitated proteins were visualized on 
silver-stained gels (right) or caspase-3 Western blot analysis (left). 
Molecular weight markers, immunoglobulin heavy chain
(HC), light chain (LC), and caspase-3 (C3) are shown. (B) 
S-Nitrosylation of caspase-3. The SNO-derived chemilumines-
cence signal of Ig control (Ig) and caspase-3 (C3) immunoprecip-
itations obtained from mitochondrial (M) and cytoplasmic (C) 
fractions of 10C9 cells are shown. NO chemiluminescence in 
arbitrary units is plotted on the y-axis, and time is plotted on the 
x-axis. The NO released from each sample is proportional to the 
area under the curve. The data are representative of 1 of 10 sep-
arate experiments. (C) Caspase-3 is S-nitrosylated endogenously. 
The SNO-derived chemiluminescence signal of mitochondrial 
caspase-3 immunoprecipitates from CEM cells after they had 
been grown for 48 h in the presence ( NMA) or absence 
( NMA) of 4.5 mM L-NMA is shown. The data are representative 
of one of two separate experiments. Mitochondrial caspase-3 
immunoprecipitates from control cells were divided into two 
samples, one of which was exposed to UV light for 10 min 
( UV) and the other left untreated in the dark at room tempera-
ture for the same period ( UV). The SNO-derived chemilumi-
nescence signal from UV-treated and untreated samples is 
shown. The data are representative of one of four separate exper-
iments. (D) A higher percentage of mitochondrial than cytoplas-
mic caspase-3 is S-nitrosylated. S-nitrosylated proteins in cyto-
plasmic (C) and mitochondrial (M) fractions were selectively 
labeled with biotin and then purified over streptavidin-agarose
as described previously (Jaffrey et al., 2001). The purified 
S-nitrosylated proteins were then analyzed by caspase-3 Western 
blot analysis. 1 out of 100 of the total protein in the mitochon-
drial or cytoplasmic starting sample (16  g) was loaded in the 
lanes marked Total. Purified S-nitrosylated proteins obtained 
from each fraction were loaded in the lanes labeled SNO. 
Caspase-3 (C3) is indicated. 
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1999), then the stoichiometry of SNO to caspase suggests
that 
 
 
 
85% of caspase-3 zymogens in mitochondria are
S-nitrosylated compared with only 17% of zymogens in the
cytoplasmic fraction (see Fig. 4). Treatment of cells with the
NO synthase inhibitor 
 
N
 
-
 
G
 
-monomethyl-
 
L
 
-arginine (L-NMA)
for 48 h before immunoprecipitation or treatment of the im-
munoprecipitates with UV light for 10 min decreased the
level of NO detected in the immunoprecipitates, suggesting
that the NO signal is not an artifact of protein purification
(Fig. 2 C). To confirm our chemiluminescence results, we
analyzed caspase-3 S-nitrosylation using a recently described
technique in which S-nitrosylated proteins are selectively bio-
tinylated, purified over streptavidin-agarose, and then de-
tected by immunoblot (Jaffrey et al., 2001). Although the
concentration of caspase-3 was much higher in the cytoplas-
mic than in the mitochondrial lysates, similar levels of S-nitro-
sylated caspase-3 were detected in each fraction (Fig. 2 D).
This data also suggests that a higher percentage of mitochon-
drial than cytoplasmic caspase-3 is S-nitrosylated.
To rule out preferential denitrosylation of cytoplasmic cas-
pase-3 during sample preparation, we spiked our cytoplasmic
 
preparations with 60 nM of in vitro S-nitrosylated caspase-3
and then analyzed S-nitrosylated caspase-3 recovery in our
immunoprecipitates. The SNO/protein stoichiometry of cas-
pase-3 immunoprecipitates obtained from the spiked cytoso-
lic preparations was 0.75, very similar to the stoichiometry
(0.85) of mitochondrial caspase-3 immunoprecipitates. This
data suggests that caspase-3 is not preferentially denitrosy-
lated in our cytosolic preparations. In addition, treatment of
cells with L-NMA (5 mM) throughout the time of cell lysis
and immunoprecipitation had no effect on mitochondrial
caspase-3 S-nitrosylation (unpublished data). Therefore, in-
creased S-nitrosylation of mitochondrial caspase-3 is not
likely to be due to an increased exposure to NO synthase
(NOS) activity during sample preparation.
The possible sources of NO-related species that S-nitrosy-
late mitochondrial caspase-3 include a putative mitochon-
drial NOS (Kobzik et al., 1995; Ghafourifar and Richter,
1997; Tatoyan and Giulivi, 1998), NO produced by cyto-
plasmic NOS, which diffuses into the mitochondria, or
transnitrosation from S-nitrosylated species within mito-
chondria such as S-nitrosoglutathione. To determine if in-
creased S-nitrosylation of mitochondrial caspase-3 is due to
increased NO production within mitochondria, we analyzed
whether cytoplasmic caspase-3 S-nitrosylation is increased
when cells are exposed to increasing concentrations of an
NO donor. Exposure of cells to 0, 10, 100, or 1,000 
 
 
 
M of
the NO donor S-nitrosopenicillamine for 24 h did not in-
crease S-nitrosylation of immunoprecipitated cytoplasmic
caspase-3 (unpublished data). Therefore, factors in the sub-
cellular microenvironment of cytoplasmic and mitochon-
drial caspase-3 other than NO concentration are likely to be
important determinants of S-nitrosylation.
 
Mitochondrial caspase-3 is denitrosylated after 
Fas stimulation
 
We have reported previously that S-nitrosylated caspase-3 zy-
mogen obtained from whole cell lysates is denitrosylated after
Fas stimulation (Mannick et al., 1999). To determine if mi-
tochondrial caspase-3 is denitrosylated after Fas stimulation,
we immunoprecipitated caspase-3 from mitochondrial frac-
tions of cells obtained at 0 or 2–3 h after stimulation with Fas
agonist antibody (Clone CH-11, 60 ng/ml; Upstate Biotech-
nology). Mitochondrial caspase-3 S-nitrosylation decreased
79 
 
 
 
 12% (mean 
 
 
 
 SEM, 
 
n 
 
  
 
4, 
 
p 
 
 
 
 0.01, paired Student’s
 
t
 
 test) after Fas stimulation, indicating that mitochondrial
caspase-3 is denitrosylated during Fas-induced apoptosis.
 
The majority of mitochondrial but not cytoplasmic 
caspase-9 is S-nitrosylated
 
Caspase-3 is the only caspase zymogen which has been
shown to be S-nitrosylated by endogenous NOS activity in
cells. To determine if other caspase zymogens are endoge-
nously S-nitrosylated, S-nitrosylation of mitochondrial and
cytoplasmic caspase-9 zymogens was analyzed. Caspase-9
was immunoprecipitated from mitochondrial and cytoplas-
mic fractions of two human B cell lines, BJAB and10C9.
These cell lines were chosen because they express relatively
high levels of mitochondrial caspase-9, allowing sufficient
protein to be immunoprecipitated to assess the presence of
Figure 3. S-Nitrosylation of cytoplasmic and mitochondrial 
caspase-9. Caspase-9 immunoprecipitation. Proteins were immuno-
precipitated from mitochondrial (M) or cytoplasmic (C) cellular 
fractions using a caspase-9–specific rabbit polyclonal antiserum 
(C9) or equal concentration of normal rabbit serum (NRS). Immuno-
precipitated proteins were visualized on silver-stained gels (right) 
or caspase-9 Western blot analysis (left). In the silver-stained gel, 
immunoprecipitates from whole cell lysates are shown. Molecular 
weight markers, immunoglobulin heavy chain (HC), light chain 
(LC), and caspase-9 (C9) are shown. (B) S-Nitrosylation of caspase-9. 
The SNO-derived chemiluminescence signal of control normal 
rabbit serum (NRS) or caspase-9 (C9) immunoprecipitates obtained 
from mitochondrial (M) and cytoplasmic (C) fractions of BJAB cells 
and from 30 nM (30) and 60 nM (60) S-nitrosoglutathione standards 
are shown. The data are representative of 1 of 10 separate experiments. 
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SNO bonds. Caspase-9 was immunoprecipitated with its
specific antibody but not with equal concentrations of con-
trol antibody (Fig. 3 A). Silver stain analysis revealed that
caspase-9 was the only protein brought down in detectable
amounts by the caspase-9 antiserum but not by control anti-
serum (Fig. 3 A). Chemiluminescence analysis of the immu-
noprecipitates indicated that S-nitrosylated caspase-9 was lo-
cated predominantly in the mitochondrial fraction of cells
(Fig. 3 A and Fig. 4). Treatment of the immunoprecipitates
with UV light eliminated the NO signal in the immunopre-
cipitates, again suggesting that the signal is not derived from
contaminating nitrite (unpublished data). If caspase-9 is
S-nitrosylated on a single cysteine residue, then the stoichi-
ometry of SNO to caspase suggests that 
 
 
 
68% of caspase-9
zymogens in mitochondria are S-nitrosylated compared with
only 11% of zymogens in the cytoplasmic fraction (Fig. 4).
Thus, the mitochondrial subpopulations of both caspase-3
and -9 zymogens are the primary targets of S-nitrosylation in
cells.
 
S-Nitrosylation is not required to target caspase-3 
to mitochondria
 
It is possible that S-nitrosylation, like phosphorylation, lo-
calizes proteins to specific subcellular compartments (Teruel
and Meyer, 2000). To determine if S-nitrosylation targets
caspase-3 to mitochondria, cells were grown for 48 h in the
presence of NOS inhibitors. NOS inhibition decreased cas-
pase-3 S-nitrosylation (Fig. 2 C) but had no affect on mito-
chondrial caspase-3 levels (Fig. 5 A). In addition, mutation
of the catalytic site cysteine of caspase-3 to an alanine did
not alter mitochondrial caspase-3 levels (Fig. 5 B), despite
inhibiting caspase S-nitrosylation (Mannick et al., 1999).
These data suggest that S-nitrosylation is not required to tar-
get caspase-3 to mitochondria.
In summary, the results demonstrate that the majority of
mitochondrial, but not cytoplasmic, caspase-3 zymogens are
S-nitrosylated in resting cells. Since caspase-3 is S-nitrosy-
lated on its catalytic site cysteine (Mannick et al., 1999) and
this inhibits enzyme activity (Dimmeler et al., 1997; Kim et
al., 1997a,b, 2000; Li et al., 1997a; Mannick et al., 1999;
Rossig et al., 1999), S-nitrosylation is likely to play a partic-
ularly important role in regulating mitochondrial caspase-3
function. We have also shown that mitochondrial caspase-9
is S-nitrosylated, raising the possibility that S-nitrosylation is
a general mechanism by which mitochondrial caspase activ-
ity is controlled. Although the S-nitrosylated cysteine resi-
due(s) of caspase-9 has not been identified, S-nitrosylation
of the active site thiol of caspase-3, and perhaps caspase-9,
may prevent inappropriate caspase autoactivation in mito-
chondria when zymogens are brought into relatively close
proximity in the intermembrane space.
S-Nitrosylation of proteins has been suggested to play a
role comparable to phosphorylation in regulating signaling
pathways (Stamler et al., 1992). Phosphorylation involves
the reversible covalent attachment of a phosphate group to
serine, threonine, or tyrosine residues on proteins, whereas
nitrosylation involves the reversible covalent attachment of
Figure 4. Caspase-3 and -9 are S-nitrosylated more extensively in 
mitochondria than cytoplasm. The SNO content (nM) of caspase-3 
and -9 was determined by subtracting the SNO-derived chemilumi-
nescence signal in control immunoprecipitates (background) from 
the signal in caspase-3 or -9 immunoprecipitates. Protein concen-
trations (nM) were determined by silver stain analysis using known 
concentrations of caspase-3 (BD PharMingen), caspase-9 (Medical 
and Biological Laboratories Co., Ltd.), and BSA standards. The 
SNO/caspase stoichiometry of mitochondrial and cytoplasmic 
caspase-3 and -9 are shown. The data represents the mean   SEM 
of 10 separate experiments. *p   0.02; 
†p   0.04.
Figure 5. S-Nitrosylation does not target caspase-3 to mitochondria. 
(A) NOS inhibition does not decrease mitochondrial caspase-3 
levels. CEM cells were grown in the presence ( ) or absence ( ) 
of the NOS inhibitor N-
G-nitro-L-arginine (5 mM). After 48 h, a 
caspase-3 (C3) Western blot of equal protein concentrations from 
mitochondrial (Mito) and cytoplasmic (Cyto) fractions were per-
formed. The blot is representative of one of three separate experi-
ments. Similar results were obtained using the NOS inhibitor L-NMA. 
Molecular weight markers are indicated on the left. (B) Mutation 
of the catalytic site cysteine does not decrease mitochondrial 
caspase-3 levels. MCF-7 cells, which do not express caspase-3, 
were stably transfected with plasmids expressing wild-type 
procaspase-3 (WT) or procaspase-3 in which the catalytic site cys-
teine was mutated to an alanine (Mut) (Mannick et al., 1999). A cas-
pase-3 Western blot of equal concentrations of mitochondrial and 
cytoplasmic fractions was performed. The data is representative of 
one of three separate experiments. 
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an NO group to cysteine residues. One of the differences be-
tween phosphorylation and S-nitrosylation is that the SNO
bond is easily reduced and therefore less stable than the pro-
tein–phosphate bond. This has made characterization of
SNO proteins difficult and led to questions regarding their
intracellular stability. The factors that influence intracellular
SNO protein formation and stability include pO2 (Eu et al.,
2000), pH, redox environment (Stamler, 1994; Stamler et
al., 1997), the intracellular location of NOS, the different
chemistries of the various NO species that react with thiols
(Stamler, 1994), the reactivity of the target thiol itself, which
can vary sixfold (Stamler et al., 1997), and the possibility of
enzymes comparable to kinases and phosphatases that cata-
lyze the attachment or removal of NO groups from thiols
(Stamler et al., 1997; Gaston, 1999; Fang et al., 2000). Of
note, the rate constant for formation of the inorganic S-nitro-
sylating intermediate nitrogen dioxide from NO is substan-
tially higher in lipid membranes (which are abundant in mi-
tochondria) than in aqueous solution (Liu et al., 1998).
Our findings are the first to suggest the S-nitrosylation
state of a given protein may depend on its subcellular loca-
tion. Since many of the factors listed above that influence
the formation and stability of S-nitrosylated proteins are
likely to vary between subcellular compartments, it is possi-
ble that certain cellular microenvironments, such as the mi-
tochondrial intermembrane space, are privileged sites favor-
ing SNO protein stability. During apoptosis, mitochondrial
caspase-3 is released into the cytoplasm, and caspase-3 is
denitrosylated (Mancini et al., 1998; Mannick et al., 1999;
Samali et al., 1999). We speculate that movement of pro-
teins out of privileged sites into environments that do not fa-
vor SNO stability may be a mechanism involved in protein
activation by denitrosylation.
 
Materials and methods
 
Materials
 
RPMI 1640, FCS, penicillin, streptomycin, and 
 
L
 
-glutamine were pur-
chased from Cellgro/Mediatech. Caspase-3, caspase-9, cytochrome 
 
c
 
, and
SOD1 antibodies were purchased from BD Transduction Laboratories. Cy-
tochrome oxidase antibody (subunit 1V) was purchased from Molecular
Probes. Control normal rabbit serum was obtained from the laboratory of
Dr. William Marshall (University of Massachusetts Medical School,
Worcester, MA). All other chemicals were purchased from Sigma-Aldrich.
 
Cell lines
 
10C9 and BJAB are human Burkitt’s lymphoma B cell lines. CEM is a hu-
man T cell line, and U937 is a human monomyelocytic leukemia cell line.
BJAB was obtained from the laboratory of Dr. Elliott Kieff (Harvard Medical
School, Boston, MA), CEM and U937 were obtained from the laboratory of
Dr. Robert Finberg (University of Massachusetts Medical School), and
10C9 was purchased from American Type Culture Collection. MCF-7 cells
stably transfected with WT and mutant caspase-3 were generated as de-
scribed previously (Mannick et al., 1999). Cells were grown at 37
 
 
 
C, 5%
CO
 
2
 
, in RPMI 1640 supplemented with 10% heat-inactivated FCS, 2 mM
glutamine, 100 U/ml penicillin, and 100 
 
 
 
g/ml streptomycin.
 
Subcellular fractionation
 
0.7
 
   
 
10
 
8
 
 cells were washed in PBS and then resuspended in 1 ml buffer A
(150 mM NaCl, 50 mM Tris, pH 8, containing 100 
 
 
 
M EDTA and the fol-
lowing protease inhibitors: 10 
 
 
 
g/ml leupeptin, 5 
 
 
 
g/ml aprotinin, and 0.5
mM phenylmethyl-sulfonyl fluoride). The cells were then homogenized
(Kontes) until 
 
 
 
80% of the cells were stained with trypan blue. Nuclei and
unbroken cells were removed during two 10-min centrifugations at 1,000
 
 g
 
.
The postnuclear supernatant was centrifuged at 10,000 
 
g
 
 for 30 min to ob-
tain a pellet highly enriched in mitochondria. The mitochondrial pellet
was resuspended in a volume of buffer A equal to that of the postmito-
chondrial supernatant. In some experiments, the postmitochondrial super-
natant (S10) was further centrifuged at 100,000 
 
g
 
 to obtain an S100 cytoso-
lic fraction.
 
Immunoprecipitation
 
Mitochondrial or cytosolic fractions were lysed for 30 min at 4
 
 
 
C in high
salt buffer (1% NP-40, 500 mM NaCl, 50 mM Tris, pH 8, 100 
 
 
 
M EDTA,
and protease inhibitors). Insoluble material was pelleted for 10 min at
10,000 
 
g
 
 at 4
 
 
 
C. The supernatant was precleared as described previously
(Mannick et al., 1999). Cellular proteins were immunoprecipitated in the
dark with 5 
 
 
 
g of an anti–caspase-3 IgG2a monoclonal antibody, 5 
 
 
 
g of a
control IgG2a antibody (Sigma-Aldrich), 1 
 
 
 
l of a 1:5 dilution of rabbit
anti–caspase-9 polyclonal antiserum or equal concentrations of control
normal rabbit serum. The antigen–antibody complexes were isolated with
protein A–Sepharose beads for 2 h at 4
 
 
 
C. The beads were then washed
five times in high salt buffer to which 1 mM 
 
N
 
-ethyl-maleimide was added
to block free thiols and thereby prevent artifactual S-nitrosylation. Anti-
gen–antibody complexes were removed from the protein A–sepharose
beads by three 10-min incubations in 70 
 
 
 
l of 100 mM glycine (pH 3) at
4
 
 
 
C before NO measurements.
 
S-Nitrosylation measurements
 
Caspase S-nitrosylation was detected by reduction/chemiluminescence as
described previously (Fang et al., 1998) with minor modifications. Immu-
noprecipitated samples (after separation from beads) were injected into 5
ml of a solution containing 100 
 
 
 
M CuCl, 1 mM cysteine, and 0.01% anti-
foam (pH 3.5, 50
 
 
 
C) purged continuously with argon or helium (grade 5;
BOC gases). NO evolved was measured by chemiluminescence (Sievers).
Data were interpreted as raw photoelectric output (integrated using Sievers
software) and as absolute NO evolved (using NO standards generated by
S-nitrosoglutathione).
 
Detection of S-nitrosylated caspase-3 on gels
 
S-nitrosylated proteins in mitochondrial and cytoplasmic fractions were se-
lectively biotinylated and purified as described previously (Jaffrey et al.,
2001). The purified proteins were then analyzed by caspase-3 Western
blot analysis.
 
In vitro S-nitrosylation of caspase-3
 
Immunoprecipitated caspase-3 zymogen eluted from protein A–Sepharose
beads in 100 mM glycine (pH 3) was reduced with 20 mM DTT for 30 min
on ice. The DTT was removed by passage over a Sephadex G-25 column
(Amersham Pharmacia Biotech) preequilibrated with buffer B (100 mM
Hepes, pH 7.4, 140 mM NaCl, 100 
 
 
 
M EDTA, and protease inhibitors).
The protein was then incubated with 200 
 
 
 
M S-nitrosocysteine for 1 h on
ice and purified by passage over a Sephadex G-25 column. The extent of
caspase-3 S-nitrosylation was determined by chemiluminescence as de-
scribed above.
 
Western blot and silver stain analysis
 
Immunoprecipitated proteins or control BSA standards were separated on
12% SDS-PAGE. The gels were either silver stained as per the manufac-
turer’s instructions (Sigma-Aldrich), or proteins were transferred to nitrocel-
lulose and Western blots were performed as described previously (Man-
nick et al., 1999).
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